Development of Thyroid-Associated Ophthalmopathy in Patients Who Underwent Total Thyroidectomy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To report clinical characteristics of thyroid-associated ophthalmopathy (TAO) in patients who previously underwent total thyroidectomy for thyroid cancer or a benign mass of the thyroid. Materials and Methods: Of the patients who were diagnosed with TAO from March 2008 to March 2012, we performed a retrospectivechart review on those who had undergone total thyroidectomy for thyroid cancer or a benign mass of the thyroid before the occurrence of ophthalmopathy. Results: Of the 206 patients diagnosed with TAO, seven (3.4%) met the inclusion criteria. The mean age of the subjects was 47.4 years, and all were female. Six patients were diagnosed with papillary thyroid cancer, and one was diagnosed with a benign mass. The duration between total thyroidectomy and onset of TAO ranged from 3–120 months (median 48 months). Ophthalmic manifestationsvaried among cases. Except for the patient who was diagnosed with a benign mass, all patients showed hyperthyroid status and were under Synthroid hormone treatment at the time of TAO development. Five of these six patients had positive levels of thyroid-stimulating hormone (TSH) receptor autoantibodies. Conclusion: TAO rarely develops after total thyroidectomy, and the mechanism of TAO occurrence is unclear. However, most patientsshowed abnormalities in thyroid function and TSH receptor autoantibodies.
Abstract
Purpose: To report clinical characteristics of thyroid-associated ophthalmopathy (TAO) in patients who previously underwent total thyroidectomy for thyroid cancer or a benign mass of the thyroid. Materials and Methods: Of the patients who were diagnosed with TAO from March 2008 to March 2012, we performed a retrospectivechart review on those who had undergone total thyroidectomy for thyroid cancer or a benign mass of the thyroid before the occurrence of ophthalmopathy. Results: Of the 206 patients diagnosed with TAO, seven (3.4%) met the inclusion criteria. The mean age of the subjects was 47.4 years, and all were female. Six patients were diagnosed with papillary thyroid cancer, and one was diagnosed with a benign mass. The duration between total thyroidectomy and onset of TAO ranged from 3–120 months (median 48 months). Ophthalmic manifestationsvaried among cases. Except for the patient who was diagnosed with a benign mass, all patients showed hyperthyroid status and were under Synthroid hormone treatment at the time of TAO development. Five of these six patients had positive levels of thyroid-stimulating hormone (TSH) receptor autoantibodies. Conclusion: TAO rarely develops after total thyroidectomy, and the mechanism of TAO occurrence is unclear. However, most patientsshowed abnormalities in thyroid function and TSH receptor autoantibodies.
참고문헌 (21)
- Bahn RS, "Graves’ ophthalmopathy", N Engl J Med, 362, pp.726~738 (2010)
- Kuriyan AE, "The eye and thyroid disease", Curr Opin Ophthalmol, 19, pp.499~506 (2008)
- Antonelli A, "Extra-ocular muscle cells from patients with Graves’ ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ", Autoimmun Rev, 13, pp.1160~1166 (2014)
- Antonelli A, "Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases", Autoimmun Rev, 13, pp.272~280 (2014)
- Tanda ML, "Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism seen at a single center", J Clin Endocrinol Metab, 98, pp.1443~1449 (2013)
- Lehmann GM, "Immune mechanisms in thyroid eye disease", Thyroid, 18, pp.959~965 (2008)
- Jang SY, "Clinical characteristics of Graves’orbitopathy in patients showing discrepancy between levels from TBII assays and TSI bioassay", Clin Endocrinol (Oxf), 80, pp.591~597 (2014)
- 장선영, "Correlation between TSH Receptor Antibody Assays and Clinical Manifestations of Graves’ Orbitopathy", Yonsei Medical Journal, 54(4), pp.1033~1039 (2013), 연세대학교의과대학[DOI]
- Lytton SD, "A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy", J Clin Endocrinol Metab, 95, pp.2123~2131 (2010)
- Carnell NE, "Thyroid nodules in Graves’ disease: classification, characterization, and response to treatment", Thyroid, 8, pp.647~652 (1998)
- 유혜민, "Graves’ Disease that Developed Shortly after Surgery for Thyroid Cancer", Endocrinology and Metabolism, 28(3), pp.226~230 (2013), 대한내분비학회
- Kasuga Y, "Development of Graves’ disease after surgical treatment for thyroid nodules: report of four cases", Endocr J, 44, pp.567~570 (1997)
- Menconi F, "Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids", J Clin Endocrinol Metab, 92, pp.1653~1658 (2007)
- Winsa B, "Retrospective evaluation of subtotal and total thyroidectomy in Graves’ disease with and without endocrine ophthalmopathy", Eur J Endocrinol, 132, pp.406~412 (1995)
- Yoon JS, "Papillary thyroid carcinoma with thyroid-associated orbitopathy in a euthyroid state", Ophthal Plast Reconstr Surg, 23, pp.187~191 (2007)
- Eckstein AK, "Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy", Br J Ophthalmol, 93, pp.1052~1056 (2009)
- Jang SY, "Clinical features of thyroid-associated ophthalmopathy in clinically euthyroid Korean patients", Eye (Lond), 26, pp.1263~1269 (2012)
- Acharya SH, "Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review", Clin Endocrinol (Oxf), 69, pp.943~950 (2008)
- Karlsson FA, "Endocrine ophthalmopathy and radioiodine therapy", Acta Oncol, 45, pp.1046~1050 (2006)
- Woeber KA, "Graves ophthalmopathy after radiation treatment of thyroid cancer", Endocr Pract, 14, pp.419~421 (2008)
- Berg G, "Development of severe thyroid-associated ophthalmopathy in a patient with disseminated thyroid cancer treated with recombinant human thyrotropin", radioiodine and retinoic acid, 2005, pp.15, 1389~1394